Asbestosis
6
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
16.7%
1 terminated out of 6 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
Specialized Center of Research in Occupational and Immunologic Lung Disease
Oscillation Mechanics of the Respiratory System Asbestos Exposed: Early Diagnosis